logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Farmaindustria promotes the creation of a working group to promote clinical trials in primary care

Representatives of scientific societies, public administrations, researchers and pharmaceutical companies make up the group.

Clinical research at this level of care has a great opportunity for improvement and this initiative was created with this objective in mind.

Between 2004 and 2021, clinical trials involving primary care in Spain have been reduced by half, from 14% to 7.5%, according to data from the BEST project.

Grupo de trabajo de investigación clínica en Atención Primaria.

Source: farmaindustria.es

In recent years, Spain has established itself as a world leader in clinical trials, with 85% of them promoted by the pharmaceutical industry, according to the latest data from the Spanish Clinical Trials Register (REEC) at the end of November 2022. However, the excellence achieved in Spain in clinical research in hospitals has not followed the same trend in primary care, where from 2004 to 2021 participation in clinical trials has fallen from 14% to 7.5%.

To reverse this trend, Farmaindustria has promoted the creation of a mixed working group on clinical research in primary care, with the participation of the scientific societies of this level of care, researchers, autonomous communities and pharmaceutical companies. The aim is to analyse current strengths and weaknesses and define a roadmap to establish criteria of excellence for conducting clinical trials with medicines at this level of care, as well as to identify good practices that are already underway.

The first meeting of this group was held this Thursday at Farmaindustria’s headquarters in Madrid, with the participation of the Association’s Deputy Director General, Javier Urzay; the Director of the Department of Relations with the Autonomous Communities, José Ramón Luis-Yagüe, and the Associate Director of Clinical and Translational Research at Farmaindustria, Amelia Martín Uranga. Representatives from the three primary care scientific societies – the Spanish Society of General and Family Physicians (SEMG), the Spanish Society of Primary Care Physicians (Semergen) and the Spanish Society of Family and Community Medicine (Semfyc) -, from foundations and research institutes, and from the administration of five autonomous communities and eight pharmaceutical companies also attended.

In addition to extending Spanish excellence in clinical trials to primary care, this project facilitates bringing clinical trials closer to the patient in a context of proximity to their doctor. In this way, it can respond to the necessary decentralisation of clinical research, with the possibility of providing greater equity of access to all patients, regardless of where they live. This can be of great interest for Phase 3 clinical trials – the last phase before a drug is put on the market – where thousands of patients are recruited and a large number of centres are involved.

It can also be particularly useful for certain diseases that are treated at this level of care, such as cardiovascular, inflammatory or respiratory pathologies, among others. Moreover, these diseases are usually diagnosed and treated in primary care at earlier stages and with a large number of patients, which can facilitate their recruitment for clinical trials in these therapeutic areas.

In addition, promoting the participation of primary care in clinical research offers the opportunity to increase the number of cooperative trials between care levels, coordinated between health centres and hospitals, in areas such as rheumatology, oncology and endocrinology, among others.

This project is an opportunity for a country that already leads clinical trials in Europe, and this participation in research is a stimulus for the training and retention of primary care professionals, while at the same time offering an opportunity for patients to access treatments that can change the course of the disease. It thus promotes social and territorial cohesion and equity in our country.

Research in primary care also requires, as was addressed at this first meeting, the need to train professionals in this area, to provide the centres with resources to enable research and to achieve good coordination with the regional health authorities.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.